Novartis AG (NVS)
Market Cap | 198.19B |
Revenue (ttm) | 46.66B |
Net Income (ttm) | 14.85B |
Shares Out | 1.96B |
EPS (ttm) | 7.10 |
PE Ratio | 23.65 |
Forward PE | 13.59 |
Dividend | $3.78 (3.91%) |
Ex-Dividend Date | Mar 7, 2024 |
Volume | 1,524,598 |
Open | 96.28 |
Previous Close | 95.88 |
Day's Range | 96.15 - 97.20 |
52-Week Range | 90.93 - 108.78 |
Beta | 0.46 |
Analysts | Hold |
Price Target | 114.00 (+17.85%) |
Earnings Date | Apr 23, 2024 |
About NVS
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 a... [Read more]
Financial Performance
In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $114.0, which is an increase of 17.85% from the latest price.
News
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Basel, March 22, 2024 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended gr...
3 Top Stocks to Watch From the Best International Money Managers
#Morningstar #NovoNordisk #StockInvesting Managers of highly rated funds own these foreign stocks. Should you?
US appeals court revives Regeneron's antitrust lawsuit against Novartis
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Basel, March 5, 2024 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1693 shareho...
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
Basel, March 4, 2024 – Novartis today presented new data that continue to support the clinical benefits of Zolgensma® (onasemnogene abeparvovec), the only one-time gene therapy for the treatment of sp...
FANG, NVDA, CSCO, NVS: Stock Picks in the Current Market
Diamondback Energy (FANG) consistently posted some of the strongest operational and financial results among the independent producers, notes Victoria Bills. She discusses he stock picks which include ...
‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?
Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.
UK's MHRA revokes authorisation for Novartis' sickle cell drug
Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.
Goldman Sachs Says 'GRANOLAS' Stocks Are Set to Enjoy Further Gains
Large-cap European firms with a global footprint and strong balance sheets have outperformed the 'Magnificent Seven' US stocks and are poised for further gains, according to Sharon Bell, senior Europe...
This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk
For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.
Novartis to acquire German Biotech MorphoSys for $2.9B, Expanding Cancer Drug Pipeline
Novartis (NVS) has struck a deal to buy German biotech firm MorphoSys (MOR), a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), as the Swiss drugmaker expands its roster of cancer...
Novartis to bolster its oncology portfolio with acquisition of MorphoSys
Novartis AG on Monday announced it has agreed to buy German biopharmaceutical company MorphoSys AG for 2.7 billion euros ($2.9 billion).
Novartis acquiring cancer drug developer Morphosys for €2.7 billion
CNBC's Steve Kovach joins 'Closing Bell Overtime' with breaking news out of the pharmaceutical space.
Novartis acquires cancer drug developer MorphoSys for $2.9 bln
Drugmaker Novartis AG said on Monday is has acquired MorphoSys AG , a developer of cancer treatments, for 2.7 billion euros. ($2.90 billion)
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
Basel, February 05, 2024 – Novartis today announced that it has entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (FSE: MOR; NASDAQ: MOR), a Germany-based, gl...
Exclusive: Novartis in the lead to acquire cancer drug developer MorphoSys-sources
Drug maker Novartis AG is in advanced talks to acquire MorphoSys AG , a developer of cancer treatments that has a market value of 1.6 billion euros ($1.7 billion), two people familiar with the matter ...
It's shaping up to be a great quarter for Europe's biggest companies — no thanks to Europe.
Fourth-quarter earnings season in Europe is still in its early days, but the largest companies on the Continent are mostly hitting their stride.
Novartis CEO Vasant Narasimhan on Q4 earnings miss
Novartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's quarterly earnings results, the company's warning about losing exclusivity in some products, and if the sector will be acti...
Novartis Stock Slumps After Drugmaker's Earnings, Guidance Fall Short of Expectations
Novartis (NVS) announced fourth-quarter results and guidance Wednesday that fell short of analyst's expectations, and the company also ended a study on an experimental blood cancer treatment. American...
Novartis CEO: Growth drivers performing well, but product exclusivity losses creating headwinds
Vas Narasimhan, CEO of Novartis, discusses fourth-quarter results, weight loss drugs and the company's U.S. targets.
Novartis Earnings, Outlook Fall Short
Novartis shares dropped around 5% after it reported fourth-quarter earnings and sales that missed consensus expectations and issued guidance that analysts said fell short of hopes.
Novartis eyes 5% annual sales growth through 2028
Switzerland's Novartis on Wednesday updated its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings.
Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts
Ad hoc announcement pursuant to Art. 53 LR Full year (continuing operations 2) Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD) Sales growth was mainly driven ...
Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors
Basel, January 19, 2024 – Novartis today presented data from the Phase III NETTER-2 trial showing that Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 dotatate) plus long-actin...